Introduction {#sec1}
============

Initiating mutations in colorectal cancer (CRC) most commonly target the *APC* tumor suppressor gene ([@bib22]). APC is a negative regulator of WNT signaling that is required to target β-catenin for proteosomal degradation. The loss of the *APC* gene results in the accumulation of β-catenin in the nucleus, subsequent activation of WNT transcriptional targets, and ultimately adenoma formation ([@bib24]; [@bib33]; [@bib47]). Normal intestinal homeostasis is maintained by a number of intestinal stem cells (ISCs). Recent experiments have shown the presence of a cycling stem cell population marked by LGR5 along with a longer-lived population that can repopulate the crypt after injury ([@bib2]; [@bib5]). LGR5 expression marks crypt columnar stem cells that have a readily identifiable transcriptional profile termed the ISC signature. Genetic deletion of *Apc* within LGR5 ISCs leads to rapid adenoma formation, whereas deletion within more differentiated lineages leads to poorly proliferative lesions that fail to progress without additional oncogenic mutations ([@bib51]). Interestingly, although an established WNT target, LGR5 is only expressed in a subset of APC-deficient tumor cells. This may be due to LGR5 marking cells with the highest levels of WNT signaling or to co-operation of multiple pathways in conferring the LGR5 ISC phenotype.

Our previous studies have shown that the WNT target gene *Myc* is required for the phenotypes induced by *Apc* loss and that reduced levels of MYC slows intestinal tumorigenesis ([@bib1]; [@bib48]). These studies set a precedent that targeting the downstream effectors of WNT signaling may be of therapeutic benefit in colorectal cancer. In the case of MYC, although there is great interest in it as a therapeutic target ([@bib54]), in vivo inhibitors are still in development. Therefore identification of other pathways downstream of *Apc* loss, in particular those highly active in LGR5 ISCs may provide candidates to target APC-deficient cells.

One candidate pathway is RAC signaling. RAC1 is a GTPase that acts as a key signaling node modulating a diverse set of cellular processes including proliferation, apoptosis, migration, and invasion. It influences a variety of signaling pathways including MTOR, NF-κB, JNK, and reactive oxygen species (ROS) production ([@bib12]). RAC1 cycles between an inactive GDP and active GTP-bound state and is controlled by guanine nucleotide exchange factors (GEFs) (which activate RAC1) and GTPase-activating proteins (which inactivate RAC1). We previously identified MYC-dependent upregulation of a number of RACGEFs after *Apc* loss, and RACGEFs are commonly overexpressed during tumor progression ([@bib28]; [@bib48]). RAC1-activating mutations have also been discovered in melanoma and a constitutively active RAC1 isoform termed RAC1B identified in colon and lung tumor samples can promote lung tumorigenesis ([@bib18]; [@bib25]; [@bib62]). RAC1 is also required for KRAS-mediated tumorigenesis in skin and the lung, but the mechanism of how RAC1 loss suppresses tumorigenesis is still unclear ([@bib23]; [@bib45]). Therefore, it is important to elucidate how RAC1 drives tumorigenesis.

Two studies suggest that RAC1 is required for nuclear localization of β-catenin and WNT signaling ([@bib38]; [@bib60]). First, Wu and colleagues demonstrated that RAC1 is required for β-catenin nuclear localization in the developing limb bud and the effects of its deletion phenocopy those of β-catenin. As nuclear localization of β-catenin is a key event during CRC initiation if this dependency remains once *Apc* is deleted, it would suggest that RAC1 would be an excellent therapeutic target. Additionally, Phelps and colleagues demonstrated that in zebrafish, *apc* loss alone was insufficient to cause nuclear localization of β-catenin ([@bib38]). Here the consequence of *apc* loss was perturbed differentiation, which was dependent on the transcriptional repressor Ctbp1. Additional activation of Kras was required for nuclear accumulation of β-catenin and hyperproliferation after *apc* loss. The authors proposed that RAC1 activation downstream of constitutive Kras activity was the mechanism that allowed the nuclear accumulation of β-catenin. These results are controversial as a number of studies have shown that (1) β-catenin can be nuclear localized in human adenomas without KRAS mutation ([@bib37]), (2) WNT target genes can be upregulated in human adenomas without KRAS mutation ([@bib43]), and (3) murine studies have shown nuclear β-catenin and WNT target gene upregulation in adenomas from the *Apc*^*Min/+*^ mouse ([@bib47]; [@bib52]).

Therefore, given this evidence for a role of RAC1 in WNT signaling, we investigated the importance of RAC1 activation after *Apc* deletion. We show that a number of *RacGEF*s and *Rac1b* are upregulated after *Apc* deletion, which leads to increased activity of RAC1. While *Rac1* deletion did not stop the nuclear accumulation of β-catenin and activation of the majority of the TCF/LEF targets, it attenuated hyperproliferation after *Apc* loss and subsequent tumorigenesis. Finally, we show that this is due to RAC1-mediated control of ROS production and NF-κB activation.

Results {#sec2}
=======

RAC1 Is Activated after *Apc* Loss {#sec2.1}
----------------------------------

Previous microarray analysis revealed upregulation of several RACGEFs after *Apc* loss ([@bib48]). We found significant overexpression of *Vav3* and *Tiam1* transcripts after *Apc* loss in a MYC-dependent manner (as synchronous deletion of *Apc* and *Myc* returned expression levels to wild-type) ([Figure 1](#fig1){ref-type="fig"}A). Chromatin immunoprecipitation (ChIP) revealed that MYC was bound to the *Tiam1* promoter, demonstrating it is a direct MYC target ([Figure S1](#app2){ref-type="sec"}A available online). Moreover, we observed increased expression of *Rac1b* but not *Rac1* ([Figure 1](#fig1){ref-type="fig"}A). To investigate whether this led to increased RAC1 activation, we performed immunohistochemistry (IHC) using an antibody raised against RAC-GTP ([@bib45]). We observed increased, specific positivity for RAC-GTP in APC-deficient tissue that was dependent on MYC ([Figure 1](#fig1){ref-type="fig"}B). Pull-downs for active RAC1 in wild-type and APC-deficient intestinal extracts confirmed these results ([Figure S1](#app2){ref-type="sec"}B). Levels of RAC1 protein and mRNA remained unchanged ([Figures 1](#fig1){ref-type="fig"}A and [S1](#app2){ref-type="sec"}C). To assess RAC activation in human CRC, we stained a TMA containing 50 normal and 650 primary CRC tumor cores for RAC-GTP ([Figures 1](#fig1){ref-type="fig"}C and [S1](#app2){ref-type="sec"}D) ([@bib10]; [@bib36]). We found a significant (p ≤ 0.0001) increase in RAC-GTP staining intensity at all tumor stages compared to normal tissue, indicating that RAC activation is an early event in CRC. We also stained a commercial TMA for RAC-GTP, TIAM1, VAV3, and MYC and found a significant correlation between the expressions of these proteins ([Figures 1](#fig1){ref-type="fig"}D and [S1](#app2){ref-type="sec"}E). These data are consistent with previous studies suggesting that RAC1 expression (and presumably activation) is elevated in CRC ([@bib13]). Therefore, our data suggest that in mammalian cells, activation of RAC1 occurs downstream of WNT activation.

*Rac1* Deletion Inhibits Hyperproliferation and LGR5 ISC Expansion after *Apc* Loss {#sec2.2}
-----------------------------------------------------------------------------------

To assess the functional significance of RAC1 activation after *Apc* loss, we generated *vil-Cre-ER*^*T2*^ *Apc*^*fl/fl*^ *Rac1*^*fl/fl*^ (APC Rac1) mice ([@bib11]; [@bib59]). Four days after cre induction, we observed loss of both *Rac1* and *Rac1b* mRNA and RAC1 protein ([Figures 1](#fig1){ref-type="fig"}A and [S2](#app2){ref-type="sec"}A). In contrast to induced *vil-Cre-ER*^*T2*^ *Apc*^*fl/fl*^ mice (APC), the intestines from APC Rac1 mice had smaller hyperproliferative crypts with significantly reduced incorporation of BrdU ([Figures 2](#fig2){ref-type="fig"}A and [S2](#app2){ref-type="sec"}B). Acute deletion of Rac1 alone (*vil-Cre-ER*^*T2*^ *Rac1*^*fl/fl*^) did not affect crypt size, proliferation, or ISC lineage-tracing capacity ([Figures 2](#fig2){ref-type="fig"}A and [S2](#app2){ref-type="sec"}C), although increased apoptosis of villi enterocytes and intestinal barrier breakdown was observed at later time points (data not shown). This prevented later time point analysis and ruling out of potential subtle homeostatic effects over the longer term. The *vil-Cre-ER*^*T2*^ transgene also induces recombination in the colonic epithelium and the RAC1-dependent intestinal proliferation phenotype was recapitulated in this tissue ([Figure S2](#app2){ref-type="sec"}D). Thus, RAC1 is a critical component in permitting crypt progenitor hyperproliferation after *Apc* loss in the intestinal and colonic epithelia. Given previous studies reporting that RAC1 is required for accumulation of nuclear β-catenin ([@bib38]; [@bib60]), we predicted that this and downstream target gene activation should be impaired in APC Rac1 intestines. However, IHC analysis showed nuclear β-catenin in APC Rac1- (and APC-) deleted intestines ([Figure 2](#fig2){ref-type="fig"}B). Moreover, quantitative RT-PCR (qRT-PCR) of selected TCF/LEF targets that are deregulated after *Apc* loss were unchanged in APC Rac1 intestines ([Figure S2](#app2){ref-type="sec"}E) ([@bib48]). Thus, RAC1 is not required for β-catenin nuclear localization and/or its functional activity in the absence of APC. To delineate the mechanism, we compared global gene expression changes between APC and APC Rac1 intestines by microarray. Gene set enrichment analysis (GSEA) identified a significant overlap between our data set and the ISC signatures associated with LGR5+ or EPHB2 high ISCs (chi-square test with Yates's correction, LGR5 p \< 0.0001, EPHB2 p = 0.001) ([@bib2]; [@bib31]; [@bib57]). We confirmed that the ISC signature was upregulated after *Apc* loss and reverted back to wild-type levels in APC Rac1 intestines using qRT-PCR ([Figure 2](#fig2){ref-type="fig"}C). To visualize changes in the LGR5-expressing population, we generated inducible *vil-Cre-ER*^*T2*^ WT, Rac1, APC, and APC Rac1 mice carrying the *Lgr5*^*GFP-CREER*^ transgene ([@bib2]). LGR5-GFP expression is restricted to the base of the crypt in wild-type and RAC1-deficient mice by IHC ([Figure S2](#app2){ref-type="sec"}F). After *Apc* loss, there is a significant increase in the number of LGR5-GFP-positive cells that are suppressed in APC Rac1 intestines ([Figure 2](#fig2){ref-type="fig"}D). Moreover, scoring the location of LGR5-expressing cells revealed a striking expansion of the stem cell "zone" that codeletion of *Rac1* prevented ([Figure 2](#fig2){ref-type="fig"}E). This was confirmed using multiphoton microscopy on intestines ([Figures S2](#app2){ref-type="sec"}G and S2H). To investigate whether *Rac1* deletion suppressed the proliferative potential of all ISC populations, we purified crypts from APC and APC Rac1 intestines and cultured them ex vivo. Remarkably, while APC crypts formed colonies, APC Rac1 crypts did not, suggesting that RAC1 is required for the clonogenic capacity of all intestinal cell types ([Figure S2](#app2){ref-type="sec"}I). Therefore, RAC1 is required for two critical constituents of *Apc* loss, progenitor hyperproliferation and LGR5 ISC expansion.

Generation of ROS by RAC1 Allows LGR5 ISC Signature Expansion upon *Apc* Loss {#sec2.3}
-----------------------------------------------------------------------------

As RAC1 integrates many pathways, a plethora of downstream effectors could account for the phenotype that we observed. One critical cellular process requiring RAC1 is the generation of ROS. RAC1 is a member of the superoxide-generating NADPH oxidase complex, and RAC1B overexpression has been shown to lead to ROS production ([@bib4]; [@bib42]). The generation of ROS by NADPH oxidase involves the conversion of NADPH to NADP+ so its activity can be evaluated by the ratio of these molecules. We observed a shift in the NADP+/NADPH ratio in APC intestinal extracts compared to WT, indicating increased complex activity that was RAC1 dependent ([Figure S3](#app2){ref-type="sec"}A). To analyze ROS levels within the intestinal epithelium, we stained WT, Rac1, APC, and APC Rac1 intestines with the ROS-responsive dye dihydroethidium (DHE). We observed a significant increase in staining intensity in APC but not APC Rac1 intestines ([Figures 3](#fig3){ref-type="fig"}A and 3B). Thus, *Apc* loss leads to increased ROS generation in the intestinal epithelium via activation of the RAC1-containing NADPH oxidase complex. Moreover, DHE staining indicated that in WT tissue ROS generation was particularly high at the crypt base ([Figure 3](#fig3){ref-type="fig"}A). Scoring DHE fluorescence intensity based on crypt cell position showed that ROS generation was highest at cell positions 1--3 (where LGR5+ cells reside) and was absent in RAC1-deficient intestines ([Figure S3](#app2){ref-type="sec"}B). To confirm that LGR5+ cells have high levels of ROS, we isolated intestinal epithelial cells from mice carrying the *Lgr5*^*GFP-CREER*^ transgene ([@bib2]), stained them with the ROS-responsive dye CellROX Deep Red, and analyzed them by flow cytometry. We found that LGR5-GFP-expressing cells contained around 2-fold more ROS than the cell population as a whole ([Figures 3](#fig3){ref-type="fig"}C, 3D, and [S3](#app2){ref-type="sec"}C). As ROS generation at the crypt base was Rac1 dependent ([Figures 3](#fig3){ref-type="fig"}A and [S3](#app2){ref-type="sec"}B), we investigated the expression of *Tiam1*, *Vav3*, and *Rac1b* in LGR5+ cells sorted by qRT-PCR and found that all were significantly enriched, though *Rac1* levels were unchanged ([Figure 3](#fig3){ref-type="fig"}E).

We hypothesized increased RAC1-driven ROS generation may be a critical process in conferring the ISC/progenitor phenotypes associated with *Apc* loss. We tested this hypothesis in two ways. First, we assessed whether reduction of intracellular ROS levels through NAC treatment could recapitulate the phenotypes associated with *Rac1* deletion. Remarkably, treatment of APC-deficient mice with NAC strongly suppressed overexpression of the ISC signature genes (*Lgr5*, *Olfm4*, and *Rgmb*) ([Figure 4](#fig4){ref-type="fig"}A). This suppression did not extend to non-ISC WNT target genes, indicating that WNT signaling was not perturbed by this treatment ([Figure S4](#app2){ref-type="sec"}A). NAC treatment also significantly attenuated proliferation in APC intestines ([Figures 4](#fig4){ref-type="fig"}B and [S4](#app2){ref-type="sec"}B). Importantly, NAC treatment had no effect on proliferation, number of LGR5-GFP cells, or gross villus histology in WT mice (4 day and 8 week time points) ([Figure 4](#fig4){ref-type="fig"}B and data not shown). Second, we asked whether induction of ROS could rescue the reduced ISC signature in APC Rac1 intestines. Systemic treatment with the ROS-inducing compound paraquat led to increased expression of ISC marker genes in APC Rac1 intestines ([Figures 4](#fig4){ref-type="fig"}C and [S4](#app2){ref-type="sec"}C). In situ microscopy of APC Rac1 mice carrying the *Lgr5*^*GFP-CREER*^ transgene demonstrated a significant expansion of the ISC zone upon paraquat treatment ([Figure S4](#app2){ref-type="sec"}D). In WT and APC-deficient mice treated with paraquat, the majority of ISC markers were unaffected. We also observed a significant increase in proliferation in the intestines of the three cohorts of paraquat-treated mice ([Figures 4](#fig4){ref-type="fig"}D and [S4](#app2){ref-type="sec"}E). Thus, induction of ROS can induce proliferation and, in the absence of RAC1, can partially compensate for its loss.

RAC1-Driven NF-κB Signaling Mediates LGR5 ISC/Progenitor Hyperproliferation {#sec2.4}
---------------------------------------------------------------------------

We have recently demonstrated a requirement for the NF-κB transcription factor P65 in ISC expansion after β-catenin activation ([@bib51]). Given the remarkable overlap with this study, we addressed whether NF-κB signaling is an important mediator of LGR5 ISC/progenitor proliferation after *Apc* loss. We observed a significant reduction of NF-κB signaling components P65, IKKβ, and acetyl-P65 in APC Rac1 compared to APC-deficient intestines ([Figures 5](#fig5){ref-type="fig"}A, [S5](#app2){ref-type="sec"}A, and S5B). Also, NF-κB binding activity was perturbed in APC Rac1 compared to APC intestinal extracts ([Figure S5](#app2){ref-type="sec"}C). We also observed an increase in p65 binding to the promoters of *Lgr5*, *Olfm4*, and *Rgmb* after *Apc* loss that was lost upon codeletion of *Rac1* ([Figures 5](#fig5){ref-type="fig"}B and 5C). Thus, efficient activation of NF-κB signaling in the intestine requires RAC1. We next sought to functionally determine whether constitutive NF-κB signaling can compensate for *Rac1* deletion. We crossed APC Rac1 mice to mice carrying the *R26Stop*^*FL*^*ikk2ca* allele (an inducible, constitutively active *Ikk2* allele from now on referred to as IKK) to generate APC Rac1 IKK mice ([@bib49]) ([Figure 5](#fig5){ref-type="fig"}D). This model permits constitutive activation of NF-κB signaling in the absence of RAC1. This was sufficient to almost completely rescue the proliferation defect and partially rescue ISC marker expression in APC Rac1 mice ([Figures 5](#fig5){ref-type="fig"}E, 5F, and [S5](#app2){ref-type="sec"}D). Thus, NF-κB signaling is an important downstream effector of RAC1 signaling in promoting the phenotypes of *Apc* loss. We noted that neither increased ROS nor NF-κB activation were able to completely rescue the APC Rac1 deletion phenotype. This is perhaps unsurprising given that we also observed effects on a number of other pathways downstream of RAC1 signaling, such as STAT3 and MTOR, which could impinge on the phenotypes of *Apc* loss ([Figure S5](#app2){ref-type="sec"}E).

*Rac1* Deletion Prevents Transformation after *Apc* Loss {#sec2.5}
--------------------------------------------------------

Our previous studies have shown that *Apc* deletion within ISCs using *Lgr5*^*GFP-CREER*^ leads to rapid tumorigenesis ([@bib3]). Given that *Rac1* deletion prevents increased *Lgr5* expression within *Apc*-deficient crypts, we hypothesized that this would reduce the tumor-forming capacity of ISCs. To test this, we generated control *Lgr5*^*GFP-CREER*^ *Apc*^*fl/fl*^ (Lgr5 APC) and experimental *Lgr5*^*GFP-CREER*^ *Apc*^*fl/fl*^ *Rac1*^*fl/fl*^ (Lgr5 APC Rac1) mice. To induce recombination, we gave mice a daily injection of tamoxifen for 4 days (a total of four injections). Most control Lgr5 APC mice developed a lethal intestinal adenoma burden by 20 days; however, none of the Lgr5 APC Rac1 did until much later time points ([Figure 6](#fig6){ref-type="fig"}A). When they did succumb to adenoma formation, all adenomas expressed *Rac1*, indicating that they most likely arose from cells in which *Rac1* deletion had not occurred ([Figure S6](#app2){ref-type="sec"}A). Histological analysis revealed that in contrast to the adenomas found in controls, Lgr5 APC Rac1 mice developed numerous cystic structures and micro adenomas ([Figures 6](#fig6){ref-type="fig"}B and 6E). These lesions phenotypically resemble those that arise via *Apc* deletion outside the stem cell zone ([@bib3]) and had a very low proliferative index ([Figure 6](#fig6){ref-type="fig"}E). Despite high levels of nuclear β-catenin, they had reduced levels of LGR5-GFP, suggesting that RAC1 activity is essential for tumor growth and the efficient expansion of LGR5 cells after *Apc* loss ([Figures 6](#fig6){ref-type="fig"}F, 6G, and [S6](#app2){ref-type="sec"}B). LGR5 also marks colonic stem cells, and deletion of *Apc* with *Lgr5*^*GFP-CREER*^ leads to formation of colonic adenomas ([@bib3]). At the time of sacrifice, few colonic adenomas were macroscopically visible in either Lgr5 APC or Lgr5 APC Rac1 mice. However, microscopic analysis uncovered numerous aberrant crypt foci and micro adenomas in the colons of Lgr5 APC mice that stained positive for nuclear β-catenin ([Figure S6](#app2){ref-type="sec"}C and data not shown). We observed a significant reduction in the number of these lesions in the colons of Lgr5 APC Rac1 mice ([Figure S6](#app2){ref-type="sec"}D), with the majority of these mice (6/8) being tumor free. Thus, RAC1 is required for intestinal and colonic adenoma formation after *Apc* loss. To test whether ROS production by RAC1 was also important, we treated Lgr5 APC mice with NAC. This led to a significant extension of tumor-free lifespan, further emphasizing the role ROS plays in intestinal transformation ([Figure 6](#fig6){ref-type="fig"}H).

As CRC progresses, tumors accumulate additional mutations, of which the activation of KRAS^G12D^ (Kras) is one of the most common ([@bib6]). Therefore, we generated *vil-Cre-ER*^*T2*^ *Apc*^*fl/fl*^ *Kras*^*G12D/+*^ (APC Kras) and *vil-Cre-ER*^*T2*^ *Apc*^*fl/fl*^ *Kras*^*G12D/+*^ *Rac1*^*fl/fl*^ (APC Kras Rac1) mice. Three days after induction, we purified crypts from these mice and assessed their tumor formation capacity by injecting them into nude mice. Strikingly, crypts from APC Kras intestines were able to efficiently form tumors, whereas those from APC Kras Rac1 animals did not ([Figure 6](#fig6){ref-type="fig"}I). In the two out of six cases in which delayed tumor formation occurred from Apc Kras Rac1 crypts, they were found to express *Rac1*, indicating that these grew from rare crypts that had not lost *Rac1* (data not shown). Together, these data strongly indicate an essential role for RAC1 in intestinal adenoma formation.

A recent study has demonstrated that LGR5 marks a population of cancer stem cells (CSCs) within mouse intestinal adenomas ([@bib50]). As RAC1 permits the proliferation of LGR5 ISCs after *Apc* loss, we asked whether RAC1 is important for maintaining this population in established tumors. Specifically, we wanted to assess the impact of deletion of *Rac1* from the LGR5+ population within adenomas. For this, we intercrossed mice carrying the *Apc*^*1322T*^ allele ([@bib40]) to *Lgr5*^*GFP-CREER*^ mice. To test recombination within tumors, we aged *Lgr5*^*GFP-CREER*^ *Apc*^*1322T*^ carrying the *Rosa26-RFP* reporter ([Figure S6](#app2){ref-type="sec"}E) to 60 days, when mice have small tumors and induced recombination with tamoxifen. In agreement with previously published work, we observed lineage tracing within both wild-type epithelium and in adenomas, with marked RFP-positive clones 3 weeks after induction in both ([Figures S6](#app2){ref-type="sec"}F and S6G) ([@bib50]). Given that we were able to induce recombination within adenomas, we aged *Lgr5*^*GFP-CREER*^ *Apc*^*1322T/+*^ *Rac1*^*fl/*fl^ mice until they developed signs of intestinal tumor burden (weight loss and anemia) and induced recombination. *Rac1* deletion significantly reduced the number of LGR5-GFP-positive cells within the tumors ([Figure 6](#fig6){ref-type="fig"}J). Moreover, the reduction in the number of LGR5-GFP-positive cells was partially ablated by concurrent treatment of mice with paraquat ([Figure S6](#app2){ref-type="sec"}J). Thus, RAC1 is required for LGR5 maintenance in intestinal adenomas.

Discussion {#sec3}
==========

Here, we demonstrate a critical requirement for RAC1 in intestinal transformation after *Apc* loss ([Figure 7](#fig7){ref-type="fig"}). In contrast to previous studies suggesting that RAC1 is required for nuclear localization of β-catenin ([@bib60]), we find that RAC1 acts downstream of constitutive WNT signaling to promote progenitor cell proliferation and expansion of the LGR5 ISC population. This may reflect a difference between the effects of WNT3A stimulation and *Apc* loss or may indicate a tissue-specific role for RAC1 in β-catenin activation. We find that the dependence on RAC1 for crypt hyperproliferation is translated to a tumor model driven by *Apc* loss in LGR5 ISCs. These findings are striking as other oncogenic mediators overexpressed after *Apc* loss, including CYCLIN D1/D2, CD44, and MBD2, show much less dramatic effects on crypt hyperproliferation or intestinal tumorigenesis ([@bib7]; [@bib39]; [@bib61]). As RAC1 also suppresses proliferation of APC-deficient cells after KRAS activation, we propose that it is essential for intestinal transformation.

Mechanistically, these phenotypes depend on RAC1-driven production of ROS and NF-κB signaling. The role of ROS in stem cell maintenance, cellular transformation, and CSC survival appears to be context and tissue specific. In proliferative neural stem cells, high levels of ROS regulate self-renewal by driving PI3K/AKT signaling ([@bib26]). Conversely, hematopoietic stem cells are sensitive to ROS levels and higher levels limit their lifespan ([@bib21]). Additionally, although production of ROS via NOX1 upregulation is important for tumorigenesis ([@bib32]), it has been reported that low levels of ROS in CSCs help protect against radiotherapy-induced DNA damage ([@bib9]). Our data suggest that after *Apc* loss, LGR5 ISC/progenitor cell expansion is a critical process during tumor initiation and is dependent on RAC1-driven ROS production. Given that LGR5 ISCs maintain high levels of ROS but are not dependent on it, we would hypothesize that increased RAC1-ROS is critical for proliferation outside the normal niche ([Figure 7](#fig7){ref-type="fig"}). RAC1 is also required for efficient NF-κB signaling after *Apc* loss and, importantly, constitutive activation of NF-κB in the absence of RAC1 partially rescued the attenuated proliferation and ISC expansion phenotypes. We also found that loss of RAC1 prevented p65 recruitment to the promoters of ISC genes after *Apc* deletion. Our findings are similar to those observed with p65 deletion after β-catenin activation and suggest that after *Apc* loss, LGR5 ISC marker genes require both β-catenin and p65 for full transcriptional activation ([@bib51]). RAC1 deficiency prevents this by impairing NF-κB signaling, despite β-catenin nuclear accumulation. The finding that ROS and NF-κB both play important roles in intestinal tumor initiation indicates a role for inflammation in this process. Interestingly, a recent report outlines a role for inflammatory pathways in progenitor cell transformation in the foregut ([@bib29]). Thus, it is tempting to speculate that inflammatory pathways are common mediators of stem/progenitor transformation in multiple tissues.

The LGR5 ISC Signature and CRC {#sec3.1}
------------------------------

There is evidence of two different ISC populations ([@bib2]; [@bib46]). One is highly proliferative, located at the crypt base, and marked by LGR5 and the other is relatively quiescent, label retaining, and expresses BMI1. The focus of our study was on the proliferative LGR5 population and we have not directly addressed whether RAC1 is required for the transformation of BMI1 ISCs. A level of hierarchy between ISC populations has been proposed. Under normal homeostatic conditions, Lgr5 ISCs populate the intestine, but this population can be depleted during times of intestinal stress. When this occurs, Bmi1+ cells can produce Lgr5 ISCs and subsequently repopulate the intestine ([@bib56]). Interestingly, LGR5+ cells are also capable of generating the +4 population ([@bib55]). This would argue against a strict hierarchical relationship between these populations and instead indicate that, depending on various contexts, these ISC populations are interchangeable. The location, function, and plasticity of ISC populations are still subject to keen debate. Recent data has argued that LGR5+ cells express markers of alternative ISC populations and that immediate progenitor cells can regain stemness after crypt damage ([@bib34]; [@bib58]). Perhaps the simplest explanation is that LGR5+ ISCs are defined by their crypt location and progenitor cells can regain ISC properties if they enter the LGR5+ niche. Interestingly, we observed LGR5+ cells throughout the crypt after *Apc* loss, and this is dependent on RAC1. Perhaps this is why RAC1 deletion and ROS inhibition do not affect normal LGR5 ISC function, i.e., these factors are critical for unrestrained proliferation outside the conventional niche. It should be noted that despite being expanded after *Apc* loss, the LGR5+ zone does not encompass all APC-deficient cells and *Apc* deletion alone in LGR5− cells does not lead to tumorigenesis. Thus, other mutations are probably required to permit tumor formation from non-ISCs. We have recently shown that activation of KRAS in concert with *Apc* loss can induce dedifferentiation of villus enterocytes, leading to tumor formation ([@bib51]). It would be interesting to determine whether this process is RAC1 dependent. Given the plasticity of the normal intestine, this may also relate to how intestinal CSCs behave. If multiple CSC populations exist and are interconvertible, then so-called stem cell therapies, which specifically target a particular subpopulation of cells would be unlikely to prove beneficial. As specific CSC populations are depleted, they may be rapidly repopulated from alternative "reserve" CSCs or progenitor populations. In this case, it would be important to target both the CSCs and the proliferative capacity of their descendants. In this regard, our data demonstrate that RAC1 would be a particularly attractive candidate to target these populations. *Rac1* deletion suppressed both LGR5 ISC and progenitor hyperproliferation after deletion of *Apc* and prevented tumor formation from LGR5+ cells. Importantly, deleting *Rac1* also suppressed proliferation of cells with activated KRAS, thus expanding the potential range of tumors likely to respond to RAC1 inhibition.

It is currently unclear whether LGR5 marks APC-deficient ISCs. LGR5 marks a CSC population with tumor lineage-tracing properties in murine adenomas and LGR5+ APC-deficient cells have enhanced in vitro clonogenicity over LGR5− cells, but no in vivo clonogenicity data are available ([@bib50]). We have shown that LGR5 ISC expansion, in vitro clonogenicity of APC crypts, and adenoma initiation are RAC1 dependent. However, as sorted cells from adenomas do not transplant, we were not able to determine their clonogenicity in vivo. Thus, we cannot state categorically that RAC1 is required for APC-deficient ISC function. Two recent studies have suggested very different outcomes for CRC patients with high levels of LGR5 ISC markers. Merlos-Suarez and colleagues have shown that expression of EphB receptors is closely correlated with LGR5 and other ISC markers in CRC, and those cancers with high levels of these markers had a greater chance of relapse ([@bib31]). In contrast, de Sousa E Melo and colleagues showed that while high levels of WNT signaling marks CSC populations, those cancers in which the promoters of LGR5 ISC markers were methylated were more likely to relapse ([@bib8]). Thus, it is not clear how well LGR5 ISC marker expression defines CSCs in human tumors and how this is linked to disease progression.

RAC1 as a Therapeutic Target? {#sec3.2}
-----------------------------

We previously demonstrated that deletion of *Myc* was sufficient to rescue all of the phenotypes of *Apc* loss. Although *Rac1* deletion did not completely recapitulate this, the comprehensive suppression of tumor formation suggests that RAC1 is required for transformation after *Apc* loss. As the majority of CRCs contain *APC* mutations, this has been the focus of our study. However, it would be interesting to determine whether *Rac1* deletion also suppresses tumorigenesis in *Apc*-independent murine CRC models ([@bib17]; [@bib27]). Thus, RAC1 may be a worthwhile therapeutic target during the early stages of CRC. Interestingly, our data indicate that ROS and NF-κB are two parallel pathways involved in promoting ISC/progenitor proliferation downstream of RAC1. It should be noted that activation of ROS or NF-κB was not sufficient to completely rescue the phenotypes associated with *Rac1* loss. This is important in two respects. First, it demonstrates how robust the requirement for RAC1 is to intestinal tumor formation. As a key signaling node that integrates numerous downstream signaling pathways, the potential therapeutic benefits of targeting it should be high. Also, it would likely increase the range of tumors that would be sensitive to its inhibition and reduce the scope for drug resistance to develop. Second, it indicates that the RAC1 phenotype may also involve additional downstream pathways. Indeed, activation of two other known target pathways of RAC1, MTOR ([@bib44]) and STAT3 ([@bib53]), were attenuated in intestines lacking APC and RAC1. Both of these pathways have been shown to reduce though not prevent polyposis in the *Apc*^*Min/+*^ mouse ([@bib14]; [@bib35]). This may also explain why our results do not perfectly phenocopy studies on any of the RAC1-modified factors that we have examined. For example, *Ikkβ* deletion in an AOM/DSS-driven model does not completely prevent tumorigenesis, whereas in our model, *Rac1* deletion does ([@bib16]). Thus, the combined suppression of a number of downstream effectors appears to have a much more profound effect than deleting them individually. Thus, if efficient RAC1 inhibitors remain elusive, it may be worth combining inhibition of these downstream pathways. Another question that remains is what happens at more advanced stages of CRC. Would other mutations overcome the dependence of RAC1? It is interesting to note that in the case of mTOR inhibition, additional KRAS mutation strongly suppresses the efficacy of rapalogs in mouse models ([@bib19]). We have demonstrated that RAC1 is essential for the transformation of KRAS-mutated crypts. Given previous reports that the transformation activity of KRAS is dependent on RAC1 ([@bib41]), it seems likely that RAC1 would remain an efficacious target even in the setting of a KRAS mutation.

In summary, we have elucidated an important axis downstream of WNT/MYC signaling after *Apc* loss that is crucial for LGR5 ISC/progenitor hyperproliferation and hence tumorigenesis.

Experimental Procedures {#sec4}
=======================

Mouse Experiments {#sec4.1}
-----------------

All experiments were performed under the UK Home Office guidelines. The background of mice were as follows: *AhCre* experiments were at least ten generations C57Bl6J, *Apc*^*1322T*^ experiments were at least five generations C57Bl6J, *VilCre-ER* experiments were performed on a mixed background (50% C57Bl6J, 50% S129). The alleles used for this study were as follows: *c-Myc*^*fl*^ ([@bib48]), *AhCre* ([@bib20]), *Apc*^*580S*^ ([@bib48]), *Rac1*^*fl*^ ([@bib59]), *VilCre-ER* ([@bib11]), *Lgr5-CreER* ([@bib2]), *ROSA-tdRFP* ([@bib30]), and *R26Stop*^*FL*^*ikk2ca* ([@bib49]). Recombination by *VilCreER* was induced with one intraperitoneal (i.p.) injection of 80 mg/kg tamoxifen per day for 4 days. Analyses of VilCreER-induced mice were at day 4 after induction. GFP lineage tracing was performed by inducing recombination by *AhCre* using a single i.p. injection of 80 mg/kg β-napthoflavone and analyzing GFP expression 14 days later. Mice carrying the *Lgr5-CreER* transgene were given one i.p. injection of 120 mg/kg tamoxifen, followed by one daily i.p. injection of 80 mg/kg tamoxifen for 3 days. This protocol was also used for inducing recombination within preformed adenomas. For ROS inhibition, 0.5% N-acetyl cysteine was added to drinking water for 1 week prior to Cre induction by tamoxifen treatment. Treatment with paraquat was 10 mg/kg i.p. injection every other day starting 2 days prior to tamoxifen induction.

Immunohistochemistry {#sec4.2}
--------------------

Standard immunohistochemistry techniques were used throughout this study. Primary antibodies and concentrations can be found in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}. For each antibody, staining was performed on at least three mice of each genotype and average staining intensity over the entire tissue area was scored. Representative images are shown for each staining.

Microarray Analysis {#sec4.3}
-------------------

We reverse transcribed 1 μg of total RNA isolated from intestinal tissue was to cDNA and hybridized to Affymetrix Mouse Genome 430 2.0 microarrays. Cell files of six samples were normalized and analyzed in Partek Genomics Suite Software. RMA normalization and log2 transformation of the data was followed by the differential gene expression analysis using ANOVA and post hoc linear contrasts between all pairs of experimental conditions. Multiple test corrections were performed for all calculated p values. Finally, the fold change values were considered in ranking genes of interest. Enrichment analysis was performed with chi-square test with Yates's correction ([@bib15]).

Additional methods are in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S6 and Supplemental Experimental ProceduresTable S1, related to Figure 3. Step Up Changes in ExpressionList of significantly altered genes APC versus APC Rac1, step up.Table S2, related to Figure 3. Rank Product Changes in ExpressionList of significantly altered genes APC versus APC Rac1, rank product.

All authors are supported by Cancer Research UK. K.B.M. is funded by an AICR grant. The research leading to these results has received funding from the European Union Seventh Framework Programme FP7/2007-2013 under grant agreement number 278568. Thanks to histology, microscopy, and the BSU for enabling this work to be performed and Florian Greten for discussions. We thank Victor Tybulewicz for *Rac1* flox and Ian Tomlinson for *Apc*^*1322T/+*^ mice. The *ROSA-tdRFP* mice were imported from the EMMA repository (strain 02112) and were a kind gift from Hans Jorg Fehling. We thank David Tuveson and Tim Humpton for help with ROS staining. We thank Bryan Miller for help preparing the manuscript. O.J.S., K.B.M., and F.R.G. conceived and designed the project. K.B.M., P.C., E.J.M., R.A.R., D.J.H., S.S., G.K., E.-L.O., D.A., and P.T. performed the experiments and analyzed the data. K.B.M., O.J.S., P.C., D.J.H., E.J.M., and K.I.A. interpreted the data. O.J.S, K.B.M., P.C., and R.A.R. wrote the manuscript.

![RAC1 Activity Is Increased after *Apc* Loss\
(A) qRT-PCR of *Tiam1*, *Vav3*, *Rac1b*, and *Rac1* (error bars represent SD; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; t test, n = 3).\
(B) IHC for RAC-GTP in WT, APC, APC Myc, and Rac1 intestines. Red arrows indicate epithelial expression, and black arrows show immune cells in the villus compartment with very high positivity.\
(C) Histoscores of human CRC TMA cores stained for RAC-GTP (Mann Whitney).\
(D) Table comparing levels of active RAC, TIAM1, VAV3, and MYC in human CRC samples. All experiments are 4 days after induction. Scale bars represent 100 μm. See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![RAC1 Is Required for Hyperproliferation and LGR5 ISC Expansion after *Apc* Loss\
(A) Quantification of BrdU IHC in WT, Rac1, APC, and APC Rac1 intestines (Mann Whitney, n = 4).\
(B) β-catenin IHC on WT, Rac1, APC, and APC Rac1 intestines. Nuclear β-catenin is found throughout the crypt in APC and APC Rac1 tissue (black arrows). Histoscoring identified a significant increase in nuclear positivity after *Apc* loss (p = 0.04, Mann Whitney, n = 3) that was unchanged in APC Rac1.\
(C) qRT-PCR of three ISC markers (error bars represent SD; t test, n = 3, ^∗^p \< 0.05, ^∗∗^p \< 0.01).\
(D) Quantification of LGR5-GFP+ cell numbers.\
(E) Cumulative frequency scoring of LGR5-GFP cell position (error bars represent SEM). All experiments 4 days after induction. Scale bars represent 100 μm. See also [Figure S2](#app2){ref-type="sec"} and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.](gr2){#fig2}

![RAC1 Is Required for ROS Production in the Intestine\
(A) Dihydroethidium (DHE) staining of frozen sections from WT, Rac1, APC, and APC Rac1 intestines; DAPI counterstain.\
(B) Quanitification of DHE staining (error bars represent SD; t test, n = 3, ^∗^p \< 0.05, ^∗∗^p \< 0.01).\
(C) Representative fluorescence-activated cell sorting (FACS) plot of CellROX Deep Red-stained epithelial cells from an *Lgr5*^*GFP-CREER*^-expressing mouse.\
(D) Quantification of CellROX Deep Red staining (error bars represent SEM; t test, n = 3, ^∗∗∗^p \< 0.001).\
(E) Expression of Rac signaling components and control ISC markers in LGR5-GFP+ cells relative to LGR5-GFP− cells (error bars represent SEM; t test, n = 3, ^∗^p \< 0.05, ^∗∗^p \< 0.01). See also [Figure S3](#app2){ref-type="sec"}.](gr3){#fig3}

![ROS Is Required for Expansion of the ISC Signature\
(A) qRT-PCR of three ISC markers (error bars represent SD; t test, n = 3, ^∗^p \< 0.05, ^∗∗^p \< 0.01).\
(B) Quantification of BrdU staining of intestinal crypts from WT, APC, WT + NAC, and APC + NAC mice (Mann Whitney, n = 4).\
(C) qRT-PCR of three ISC markers, downregulated in APC Rac1-deficient intestines (AR) and upregulated upon treatment with paraquat (AR + PQ) (error bars represent SD; t test, n = 3, ^∗^p \< 0.05, ^∗∗∗^p \< 0.001). APC + PQ has been removed for clarity and is included in [Figure S4](#app2){ref-type="sec"}C.\
(D) Quantification of BrdU positivity (Mann Whitney, n = 6). All experiments are 4 days after induction. Scale bars represent 100 μm. See also [Figure S4](#app2){ref-type="sec"}.](gr4){#fig4}

![NF-κB Signaling after *Apc* Loss Requires RAC1\
(A) P65 IHC shows decreased expression in APC Rac1 crypts.\
(B) ChIP of P65 to the *Lgr5*, *Olfm4*, and *Rgmb* promoters and a control region (error bars represent SD; Mann Whitney, n = 3, p = 0.04).\
(C) Control ChIP showing no binding to ISC promoters of a nonspecific IgG (error bars represent SD).\
(D) Crossing strategy to generate Vil APC Rac1 IKK mice.\
(E) Quantification of BrdU positivity (Mann Whitney, n = 4).\
(F) qRT-PCR of three ISC markers showing increased expression in APC Rac1 mice after NF-κB activation (error bars represent SEM; t test, n = 3, ^∗^p \< 0.05). All experiments were performed 4 days after induction. Scale bars represent 100 μm. See also [Figure S5](#app2){ref-type="sec"}.](gr5){#fig5}

![RAC1 Is Required for Tumorigenesis Downstream of *Apc* Loss\
(A) Compared to Lgr5 APC, Lgr5 APC Rac1 mice were strongly protected against tumorigenesis (Kaplan Meier, p \< 0.0001, n = 15).\
(B and C) Lgr5 APC mice developed adenomas (B, H&E) that were highly proliferative (C, BrdU).\
(D and E) Lgr5 APC Rac1 mice predominantly developed small intestinal lesions or cysts (D, H&E) that were poorly proliferative (E, BrdU IHC, red arrows). BrdU incorporation was higher in neighboring normal intestine (black arrows).\
(F and G) GFP IHC showing high levels of Lgr5-GFP staining in Lgr5 APC adenomas (F) compared to Lgr5 APC Rac1 lesions (G).\
(H) NAC treatment protected Lgr5 APC mice from intestinal tumorigenesis (Kaplan Meier, p = 0.001, n = 7).\
(I) Tumor volume scores of allografts derived from 100 APC Kras and APC Kras Rac1-purified crypts (error bars represent SD; t test, n = 3, ^∗^p \< 0.05, ^∗∗^p \< 0.01).\
(J) Quantification of FACS analysis demonstrating a significant reduction in LGR5-GFP positivity in tumors deficient in RAC1 (Mann-Whitney, n ≥ 5). Scale bars represent 200 μm. See also [Figure S6](#app2){ref-type="sec"}.](gr6){#fig6}

![Model of RAC1-Mediated Control of Intestinal Tumor Initiation\
(A) Normal small intestinal crypt with different cell populations outlined. LGR5 ISCs have high Wnt signaling leading to high RAC1-ROS-NF-κB pathway activation.\
(B) Upon loss of *Apc*, RAC1-ROS-NF-κB pathway activation is increased throughout the crypt, permitting the expansion of the LGR5 ISC zone and progenitor cell hyperproliferation. The activation of the RAC1-ROS-NF-κB pathway throughout the crypt is critical for intestinal adenoma formation.](gr7){#fig7}
